JournalsHub
.online
Find My Journal
BC

Betty Chang

Independent Researcher

ORCID 0009-0000-6363-2484
193
Publications
20,996
Citations
46
H-Index
64
i10-Index
30.0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia OA
John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger +16 more
New England Journal of Medicine 2013
2,236
A Mitochondrial Protein Compendium Elucidates Complex I Disease Biology OA
David J. Pagliarini, Sarah E. Calvo, Betty Chang, Sunil A. Sheth, Scott B. Vafai +11 more
Cell 2008
1,991
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma OA
Michael Wang, Simon Rule, Peter Martin, André Goy, Rebecca Auer +26 more
New England Journal of Medicine 2013
1,670
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy OA
Lee Honigberg, Ashley M. Smith, Mint Sirisawad, Erik Verner, David Loury +6 more
Proceedings of the National Academy of Sciences 2010
1,520
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib OA
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gülçin Özer, Marc Zapatka +20 more
New England Journal of Medicine 2014
1,241

Publications

193 total

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma PDF

Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga et al. - Nature Medicine, 2015
Cited by 1,102 OpenAlex

Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer PDF

Andrew J. Gunderson, Megan M. Kaneda, Takahiro Tsujikawa, Abraham V. Nguyen, Nesrine I. Affara et al. - Cancer Discovery, 2015
Cited by 482 OpenAlex

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK PDF

Idit Sagiv-Barfi, Holbrook E. Kohrt, Debra K. Czerwinski, Patrick P. Ng, Betty Chang et al. - Proceedings of the National Academy of Sciences, 2015
Cited by 440 OpenAlex

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib PDF

Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gülçin Özer, Marc Zapatka et al. - New England Journal of Medicine, 2014
Cited by 1,241 OpenAlex

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia PDF

John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger et al. - New England Journal of Medicine, 2013
Cited by 2,236 OpenAlex

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma PDF

Michael Wang, Simon Rule, Peter Martin, André Goy, Rebecca Auer et al. - New England Journal of Medicine, 2013
Cited by 1,670 OpenAlex

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski et al. - Blood, 2013
Cited by 787 OpenAlex

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Susan O’Brien, Richard R. Furman, Steven Coutré, Jeff P. Sharman, Jan A. Burger et al. - The Lancet Oncology, 2013
Cited by 465 OpenAlex

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies PDF

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd et al. - Journal of Clinical Oncology, 2012
Cited by 1,110 OpenAlex

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia PDF

Martin F. M. de Rooij, Annemieke Kuil, Christian R. Geest, Eric Eldering, Betty Chang et al. - Blood, 2012
Cited by 551 OpenAlex

Research Topics

Chronic Lymphocytic Leukemia Research (110) Lymphoma Diagnosis and Treatment (66) Phagocytosis and Immune Regulation (33) Monoclonal and Polyclonal Antibodies Research (23) Galectins and Cancer Biology (18)

Frequent Co-Authors

JO
Joseph J. Buggy
8 joint publications
RI
Richard R. Furman
5 joint publications
KR
Kristie A. Blum
5 joint publications
JE
Jeff P. Sharman
4 joint publications
AM
Amy J. Johnson
4 joint publications
FO
Fong Clow
4 joint publications

Affiliations

Broad Institute
US 2008 - 2006
University of Vermont
US 2012 - 2012
The Graduate Center, CUNY
US 2021 - 2013
State University of New York
US 2004 - 2004
The University of Texas MD Anderson Cancer Center
US 2012 - 2012

External Profiles

OpenAlex Profile Search Semantic Scholar ORCID Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now